Discrete serum protein signatures discriminate between human retrovirus-associated hematologic and neurologic disease

Leukemia

Volumn 19, Issue 7, 2005, Pages 1229-1238

  Semmes, O J ^a   Cazares, L H ^a   Ward, M D ^a   Qi, L ^a   Moody, M ^a   Maloney, E ^b   Morris, J ^c   Trosset, M W ^d   Hisada, M ^b   Gygi, S ^e   Jacobson, S ^f  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d The College of William and Mary   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Diagnostics; Myelopathy; Proteomics

Indexed keywords

ALPHA INTERFERON; TRYPSIN INHIBITOR; ZIDOVUDINE;

ADULT; AFFINITY CHROMATOGRAPHY; AGED; ALGORITHM; ARTICLE; CONTROLLED STUDY; DECISION MAKING; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; EARLY DIAGNOSIS; FEMALE; GENE EXPRESSION PROFILING; HEMATOLOGIC DISEASE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REPRODUCIBILITY; RETROVIRUS; SENSITIVITY AND SPECIFICITY; SPASTIC PARAPLEGIA; SPINAL CORD DISEASE; STATISTICAL ANALYSIS; T CELL LEUKEMIA; TANDEM MASS SPECTROMETRY; TIME OF FLIGHT MASS SPECTROMETRY; VALIDATION PROCESS;

EID: 21744461764     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403781     Document Type: Article

References (22)

1. Hobbs SK, Shi G, Homer R, Harsh G, Atlas SW, Bednarski MD. Magnetic resonance image-guided proteomics of human glioblastoma multiforme. J Magn Reson Imaging 2003; 18: 530-536.
2. Bangham CR. HTLV-1 infections. J Clin Pathol 2000; 53: 581-586.
3. de The G, Bomford R. An HTLV-I vaccine: why, how, for whom? AIDS Res Hum Retroviruses 1993; 9: 381-386.
4. Tajima K. The fourth nation-wide study of adult T-cell leukemia/lymphoma (ATL) in Japan: estimates of risk of ATL and its geographic and clinical features. Int J Cancer 1990; 45: 237-243.
5. Pawson R, Richardson DS, Pagliuca A, Kelsey SM, Hoque S, Breuer J et al. Adult T-cell leukemia/lymphoma in London: clinical experience of 21 cases. Leuk Lymphoma 1998; 16: 32-50.
6. Matutes E, Chan LC. Mixed-lineage leukemia revisited: acute lymphocytic leukemia with myeloperoxidase-positive blasts by electron microscopy. Blood 1991; 77: 410-411.
7. Group LS. Major prognostic factors of patients with adult T-cell leukemia-lymphoma: a cooperative study. Leuk Res 1991; 15: 81-90.
8. Mora CA, Osame M, Jacobson S. Human T lymphotrophic virus type-I associated myelopathy/tropical spastic paraparesis (HAM/TSP): therapeutic approach. Curr Treat Options Infect Dis 2003; 5: 443-455.
9. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002; 48: 1296-1304.
10. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002; 62: 3609-3614.
11. Wadsworth JT, Somers KD, Cazares LH, Malik G, Adam BL, Stack Jr BC et al. Serum protein profiles to identify head and neck cancer. Clin Cancer Res 2004; 10: 1625-1632.
12. Vlahou A, Schellhammer PF, Mendrinos S, Patel K, Kondylis FI, Gong L et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol 2001; 158: 1491-1501.
13. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359: 572-577.
14. Qu Y, Adam BL, Yasui Y, Ward MD, Cazares LH, Schellhammer PF et al. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem 2002; 48: 1835-1843.
15. Bertone P, Kluger Y, Lan N, Zheng D, Christendat D, Yee A et al. SPINE: an integrated tracking database and data mining approach for identifying feasible targets in high-throughput structural proteomics. Nucleic Acids Res 2001; 29: 2884-2898.
16. Kosuda S, Ichihara K, Watanabe M, Kobayashi H, Kusano S. Decision-tree sensitivity analysis for cost-effectiveness of whole-body FDG PET in the management of patients with non-small-cell lung carcinoma in Japan. Ann Nucl Med 2002; 16: 263-271.
17. Semmes OJ, Feng Z, Adam BL, Banez LL, Bigbee WL, Campos D et al. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem 2005; 51: 102-112.
18. Sun Z, Yang P. Role of imbalance between neutrophil elastase and alpha 1-antitrypsin in cancer development and progression. Lancet Oncol 2004; 5: 182-190.
19. Arredouani M, Matthijs P, Van Hoeyveld E, Kasran A, Baumann H, Ceuppens JL et al. Haptoglobin directly affects T cells and suppresses T helper cell type 2 cytokine release. Immunology 2003; 108: 144-151.
20. Langlois MR, Delanghe JR. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 1996; 42: 1589-1600.
21. Turner GA. Haptoglobin A potential reporter molecule for glycosylation changes in disease. Adv Exp Med Biol 1995; 376: 231-238.
22. Lee HB, Yoo OJ, Ham JS, Lee MH. Serum alpha 1-antitrypsin in patients with hepatocellular carcinoma. Clin Chim Acta 1992; 206: 225-230.